Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based ...

COMPASS Pathways plc (CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the ...

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

View COMPASS Pathways Plc Sponsored ADR CMPS stock quote prices, financial information, real-time forecasts, and company news from CNN.

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...

In accordance with NASDAQ Listing Rule 5635 (c) (4), the equity awards were approved by the Compensation and Leadership Development Committee of Compass's Board of Directors and were made as a ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June To date, the COMP005 trial is the largest, ...

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

Compass Pathways plc (NASDAQ:CMPS) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD). Despite meeting the ...

See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.

H.C. Wainwright lowered the firm’s price target on Compass Pathways (CMPS) to $60 from $120 and keeps a Buy rating on the shares. The company reported Q3 results and provided a corporate update ...